317 related articles for article (PubMed ID: 21540555)
1. Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.
Byrne KT; Côté AL; Zhang P; Steinberg SM; Guo Y; Allie R; Zhang W; Ernstoff MS; Usherwood EJ; Turk MJ
J Clin Invest; 2011 May; 121(5):1797-809. PubMed ID: 21540555
[TBL] [Abstract][Full Text] [Related]
2. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
Byrne KT; Zhang P; Steinberg SM; Turk MJ
J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
[TBL] [Abstract][Full Text] [Related]
3. Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help.
Côté AL; Byrne KT; Steinberg SM; Zhang P; Turk MJ
PLoS One; 2011; 6(10):e26491. PubMed ID: 22046294
[TBL] [Abstract][Full Text] [Related]
4. Induction of postsurgical tumor immunity and T-cell memory by a poorly immunogenic tumor.
Zhang P; Côté AL; de Vries VC; Usherwood EJ; Turk MJ
Cancer Res; 2007 Jul; 67(13):6468-76. PubMed ID: 17616708
[TBL] [Abstract][Full Text] [Related]
5. Type I interferon signaling limits viral vector priming of CD8
Riding RL; Richmond JM; Fukuda K; Harris JE
Pigment Cell Melanoma Res; 2021 Jul; 34(4):683-695. PubMed ID: 33040466
[TBL] [Abstract][Full Text] [Related]
6. Networks of CD8
Fukuda K
Front Immunol; 2022; 13():866703. PubMed ID: 35432377
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
[TBL] [Abstract][Full Text] [Related]
8. Elimination of CD4(+) T cells enhances anti-tumor effect of locally secreted interleukin-12 on B16 mouse melanoma and induces vitiligo-like coat color alteration.
Nagai H; Hara I; Horikawa T; Oka M; Kamidono S; Ichihashi M
J Invest Dermatol; 2000 Dec; 115(6):1059-64. PubMed ID: 11121142
[TBL] [Abstract][Full Text] [Related]
9. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
[TBL] [Abstract][Full Text] [Related]
10. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
[TBL] [Abstract][Full Text] [Related]
11. IFN-γ-induced PD-L1 expression on human melanocytes is impaired in vitiligo.
Willemsen M; Krebbers G; Tjin EPM; Willemsen KJ; Louis A; Konijn VAL; Narayan VS; Post NF; Bakker WJ; Melief CJM; Bekkenk MW; Luiten RM
Exp Dermatol; 2022 Apr; 31(4):556-566. PubMed ID: 34758170
[TBL] [Abstract][Full Text] [Related]
12. Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity?
Garbelli S; Mantovani S; Palermo B; Giachino C
Pigment Cell Res; 2005 Aug; 18(4):234-42. PubMed ID: 16029417
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous vitiligo in an animal model for human melanoma: role of tumor-specific CD8+ T cells.
Lengagne R; Le Gal FA; Garcette M; Fiette L; Ave P; Kato M; Briand JP; Massot C; Nakashima I; Rénia L; Guillet JG; Prévost-Blondel A
Cancer Res; 2004 Feb; 64(4):1496-501. PubMed ID: 14973052
[TBL] [Abstract][Full Text] [Related]
14. Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo.
Wańkowicz-Kalińska A; van den Wijngaard RM; Tigges BJ; Westerhof W; Ogg GS; Cerundolo V; Storkus WJ; Das PK
Lab Invest; 2003 May; 83(5):683-95. PubMed ID: 12746478
[TBL] [Abstract][Full Text] [Related]
15. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
Yee C; Thompson JA; Roche P; Byrd DR; Lee PP; Piepkorn M; Kenyon K; Davis MM; Riddell SR; Greenberg PD
J Exp Med; 2000 Dec; 192(11):1637-44. PubMed ID: 11104805
[TBL] [Abstract][Full Text] [Related]
16. Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo.
Le Gal FA; Avril MF; Bosq J; Lefebvre P; Deschemin JC; Andrieu M; Dore MX; Guillet JG
J Invest Dermatol; 2001 Dec; 117(6):1464-70. PubMed ID: 11886510
[TBL] [Abstract][Full Text] [Related]
17. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy.
van Elsas A; Sutmuller RP; Hurwitz AA; Ziskin J; Villasenor J; Medema JP; Overwijk WW; Restifo NP; Melief CJ; Offringa R; Allison JP
J Exp Med; 2001 Aug; 194(4):481-9. PubMed ID: 11514604
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of melanocyte death in vitiligo.
Chen J; Li S; Li C
Med Res Rev; 2021 Mar; 41(2):1138-1166. PubMed ID: 33200838
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
[TBL] [Abstract][Full Text] [Related]
20. Compromised melanocyte survival due to decreased suppression of CD4
Shah F; Giri PS; Bharti AH; Dwivedi M
Exp Dermatol; 2024 Jan; 33(1):e14982. PubMed ID: 37994568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
